Precision medicine in early breast cancer—beginning of a successful story?

Over the past 20 years, advances in genomic characterization of breast cancer enabled the constant evolution of clinically relevant subtypes from immunohistochemically defined groups, to molecular profiles,1 and further individualization of driver alteration for each patient,2 with the hope of identifying the targeted ‘magic bullet’ effective for each individual. Major advances across other tumor…

Read the full article here

Related Articles